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ABSTRACT 
Objectives: The objective of the study was to determine the prevalence of metabolic syndrome in subjects with impaired fasting glucose. Since IFG 
is an intermediate stage in the development of diabetes and cardiovascular diseases it may be associated with abdominal obesity and atherogenic 
dyslipidemic profile. 
Methods: 50 Subjects with impaired fasting glucose (IFG) and 50 normoglycemic adults in the age group of 18-45 years were selected for the study. 
Fasting blood samples were collected for glucose and lipid profile. Anthropometric measurements were measured. 
Results: The prevalence of metabolic syndrome in patients with IFG according to the National Cholesterol Education Program Adult Treatment 
Panel (ATP) III was 38% and according to the Consensus definition for adult Asian Indians was 62%. The prevalence of metabolic syndrome in the 
euglycemic control group according to the National Cholesterol Education Program Adult Treatment Panel (ATP) III was 24% and according to the 
Consensus definition for adult Asian Indians was 24%. 
Conclusion: The results of this study involving patients with impaired fasting glycemia shows an increased prevalence of metabolic syndrome. 
Identification of individuals with impaired fasting glycemia and screening for the presence of metabolic syndrome will help to decrease the 
morbidity associated with this condition.  
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INTRODUCTION 
Metabolic syndrome is characterised by the presence of risk factors 
such as central obesity, increased blood pressure, impaired glucose 
tolerance, altered lipid profile mainly low high density lipoproteins 
(HDL) and high triglycerides. Patients with metabolic syndrome are 
at an increased risk for development of diabetes mellitus and 
cardiovascular diseases [1, 2]. 
Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) 
represent intermediate stages of abnormal glucose regulation that 
exists between normal glucose homeostasis and diabetes [2]. IFG is 
defined as elevated fasting plasma glucose concentration ≥ 100 
mg/dl and < 126 mg/dl [3].IFG has received increasing attention in 
recent years, because it is an intermediate stage in the development 
of diabetes and cardiovascular diseases (CVDs) [4, 5, and 6]. Many 
cardiovascular risk factors (low HDL cholesterol, hypertension and 
elevated triglycerides) are prevalent in IFG [7]. 
Hyperglycemia is seldom an isolated metabolic abnormality and is 
often the consequence of abdominal obesity and is therefore 
commonly accompanied by an atherogenic dyslipidemic profile [8]. 
It has been documented that the waist circumference is one of the 
best anthropometric markers of abdominal visceral adipose tissue 
accumulation, especially the amount of intra-abdominal or visceral 
adipose tissue [9].  
Tankova et al has demonstrated a rather high prevalence of 
metabolic syndrome in both IFG and IGT [10]. IFG is thus considered 
as a potential indicator of preventive importance for diabetes and 
CVDs [11]. 
Since IFG is the early stage of diabetes and cardiovascular diseases, 
identifying preventable risk factors associated with IFG at this early 
stage is very important in prevention and control of these diseases 
[12]. 
Lifestyle modifications have resulted in an early emergence of 
hyperglycemia and dyslipidemia especially in the urban population. 
Therefore we have analyzed a group of 50 impaired fasting glycemic 
subjects and 50 age matched euglycemic subjects for the prevalence 
of metabolic syndrome. 
MATERIALS & METHODS 
Study setting and study subjects: 
The present cross-sectional study was carried out at SRM Medical 
College Hospital and Research Centre, SRM Nagar, Potheri. The 
subjects were selected randomly from participants who attended a 
screening programme for diabetes. The protocol was approved by 
the institutional ethical committee. 
Sampling method and sample size:  
50 Subjects with impaired fasting glucose (IFG) in the age group of 
18-45 years were selected for the study. IFG is defined as elevated 
fasting plasma glucose concentration ≥ 100 mg/dl and < 126 mg/dl. 
50 Normoglycemic adults in the age group of 18-45 years formed the 
control group. The written informed consent was obtained from 
each participant.  
Patients with history of ischemic heart disease, clinical evidence of 
acute infection, renal and hepatic disease, hypo and 
hyperthyroidism, recent surgery/major trauma and patients on lipid 
lowering drugs were excluded from the study. 
Anthropometric measurements:  
BMI was calculated as the weight in kilograms divided by the square 
of the height in metres (kg/m2). The waist circumference was 
measured at the midpoint between the lower margin of the last 
palpable rib and the top of the iliac crest in mid inspiration. Arterial 
blood pressure measurements were taken as per standard 
procedures. 
Laboratory analysis: 
5 ml of venous blood was collected from the subjects after an 
overnight 12 hour fast. The serum was separated by centrifugation 
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at 3000 RPM for 10 minutes. The fasting blood sugar was estimated 
by glucose oxidase-peroxidase (GOD/POD) method; total cholesterol 
was estimated by cholesterol oxidase method: high density 
lipoprotein cholesterol (HDL-C) and LDL cholesterol by direct 
antibody inhibition method; and triglycerides by glycerol oxidase-
peroxidase method. 
The diagnosis of metabolic syndrome in the IFG and control groups 
was done on the basis of the consensus definition for adult Asian 
Indians [13] as well as according to National Cholesterol Education 
Program Adult Treatment Panel (ATP) III [14, 15]. 
According to the National Cholesterol Education Program Adult 
Treatment Panel (ATP) III, the diagnosis of metabolic syndrome was 
made when three or more of the following risk factors were present: 
a waist circumference >102 cm in men and >88 cm in women, 
fasting glucose ≥110 mg/dl, systolic blood pressure ≥130 mmHg or 
diastolic blood pressure ≥ 85 mmHg, fasting triglycerides ≥150 
mg/dl, and HDL cholesterol < 40 mg/dl in men and < 50 mg/dl in 
women. As Indians have higher body fat content than their western 
counterparts for the same BMI, lower cut-offs of waist circumference 
were used as suggested by Asia-Pacific guidelines. Waist 
circumference (WC) cut-offs were taken as >90 cm for males and 
>80 cm for females to define overweight [14, 15]. 
According to the Consensus definition for adult Asian Indians, the 
diagnosis of metabolic syndrome was made when three or more of 
the following risk factors were present: a waist circumference >90 
cm in men and >80 cm in women, fasting glucose ≥100 mg/dl, 
systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 85 
mmHg, fasting triglycerides ≥150 mg/dl, and HDL cholesterol < 40 
mg/dl in men and < 50 mg/dl in women. The current guidelines 
have suggested a BMI of ≥23 and ≥25 kg/m2 for overweight and 
obesity respectively and a waist circumference cut off for Asian 
Indians as >90 cm for men and >80cm for women[13]. 
Statistical analysis: 
The data entry and analysis was done using SPSS15 version. Chi-
square test was used to test the null hypothesis. [16] 
OBSERVATIONS & RESULTS 
In the IFG group the number of males was 41 (82%) and number of 
females was 9 (18%). In the euglycemic control group the number of 
males was 27(54%) and number of females was 23(46%). (Table I) 
Table 1: It shows the sex distribution of the study subjects 
Sex IFG group(n=50) Euglyemic Control group (n=50) 
Males 41 82% 27 54% 
Females 9 18% 23 46% 
The details of clinical biochemistry, blood pressure and 
anthropometric measurements of all the participants of the research 
are in the table 2. 
 
Table 2: It shows the clinical biochemistry, blood pressure and anthropometric parameters 
S.no Parameters Euglycemic Control group 
(n=50) 
(mean ± S.D) 
IFG group 
(n=50) 
(mean ± S.D) 
P-value 
1 Weight (Kg) 67.54 ± 9.22 72.46 ± 11.09 0.018* 
2 Height (Meters) 1.64 ± 0.07 1.66 ± 0.05 0.036* 
3 BMI (Kg/m2) 24.86 ± 2.91 26.28 ± 4.46  0.307  
4 Systole (mm of Hg) 118.08 ± 13.99 126.28 ± 13.04 0.003* 
5 Diastole(mm of Hg) 78.92 ± 9.31 85.52 ± 8.49 0.000* 
6 FBS (mg/dl) 91.88 ± 4.53 107.24 ± 5.85 0.000* 
7 Total Cholesterol (mg/dl) 157.96 ± 35.74 169.48 ± 33.30  0.099 
8 HDL (mg/dl) 43.14 ± 9.62 40.36 ± 11.09  0.184 
9 LDL (mg/dl) 107.96 ± 32.70 113.76 ± 31.12  0.366 
10 TGL (mg/dl) 101.04 ± 59.64 134.78 ± 90.07  0.030* 
11 Waist Circumference (Cm) 86.04 ± 10.10 88.92 ± 7.92  0.116 
* P value <0.05 
Based on the NCEP ATP III guidelines for diagnosis of metabolic 
syndrome, the most commonly observed components in the 
impaired fasting glycemic group of this study were high blood 
pressure(56%), low HDL(56%) followed by increased waist 
circumference (54%), high fasting blood glucose (24%) and high 
triglycerides(26%). 
Based on the NCEP ATP III guidelines for diagnosis of metabolic 
syndrome, the most commonly observed components in the 
euglycemic control group of this study were low HDL (60%) 
followed by increased waist circumference (54%), high blood 
pressure (32%) and high triglycerides (18%). 
The prevalence of metabolic syndrome in patients with IFG 
according to the National Cholesterol Education Program Adult 
Treatment Panel (ATP) III was 38% and according to the Consensus 
definition for adult Asian Indians was 62%.  
Table 3: It shows the prevalence of metabolic syndrome in the 
euglycemic and impaired fasting glycemic group. 
Criteria IFG group(n=50) Euglycemic Control 
group (n=50) 
NCEP ATP III 19 38% 12 24% 
Consensus 
definition 
31 62% 12 24% 
The prevalence of metabolic syndrome in the euglycemic control 
group according to the National Cholesterol Education Program 
Adult Treatment Panel (ATP) III was 24% and according to the 
Consensus definition for adult Asian Indians was 24%. (Table 3) 
Table 4. It shows the proportion of adults with metabolic 
syndrome according to consensus definition for adult Asian 
Indians 
IFG Group Euglycemic control group Chi square 
P value 
31 62% 12 24% x2 =14.7 
df = 1 
p = <0.001 
DISCUSSION 
Prevalence of metabolic syndrome is high among Asians including 
Indians, and is rising, particularly with the adoption of modernized 
lifestyle [17, 18, and 19]. 
In the present study, the prevalence of metabolic syndrome in 
patients with impaired fasting glycemia was found be 62% 
according to the consensus definition for adult Asian Indians [13] 
and 38% according to the National Cholesterol Education Program 
Adult Treatment Panel (ATP) III criteria [14, 15]. 
IFG is considered to be a pre diabetic state [20]. Patients with 
diabetes or IFG have a substantially higher risk of cardiovascular 
events [21]. Lifestyle modifications have resulted in an increased 
prevalence of dysglycemia in young individuals [22]. 
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In our study the increased prevalence of components of metabolic 
syndrome in patients with impaired fasting glycemia when 
compared to the euglycemic group indicates the major role of 
hyperglycemia in the pathogenesis of metabolic syndrome.  
Table 5: It shows the proportion of adults with the components 
metabolic syndrome according to consensus definition for adult 
Asian Indians. 
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Hyperglycemia due to insulin resistance is characterised by 
dyslipidemia and inflammation [23].Fasting blood glucose is often 
associated with other adverse CVD risk factors and may serve to 
identify patients with hypertension and dyslipidemia [24]. There is 
increasing evidence indicating that elevated triglyceride levels are 
independent risk factors for cardiovascular disease. [25] 
Abdominal obesity is increasingly being recognized as an important 
cardiovascular risk factor [26]. In some studies, association of 
abdominal obesity with various metabolic risk factors appears to be 
stronger than generalized adiposity [27, 28]. Common surrogate 
measures of abdominal obesity are WC and WHR [13]. 
In this study we have found the prevalence of abdominal obesity in 
patients with impaired fasting glycemia to be 54%. Higher 
abdominal fat (android obesity) is known to be a risk factor for 
hypertension, hypertriglyceridaemia, hyperinsulinaemia and 
diabetes [29, 30, 31]. 
A recent meta-regression analysis of prospective studies of WC and 
WHR as predictors of cardiovascular events has shown that both the 
measures are associated with the risk of incident CVD [32]. 
Ramchandran et al, reported the prevalence of metabolic syndrome 
to be 41% in urban area of Chennai using modified ATP-3 criteria 
among adults aged 20 to 75 yr [33]. 
Mishra et al reported 30 per cent prevalence among the urban slum 
population in Delhi [34]. Individuals with this condition have an 
elevated risk of developing cardiovascular diseases and type 2 
diabetes in different ethnic populations [35, 36]. 
The ICMR task force collaborative study reported the prevalence of 
metabolic syndrome to be 30 per cent in urban areas of Delhi and 
11% in rural Haryana using ATP-3 criteria [37]. The presence of 
metabolic syndrome was seen in 5.0 per cent rural adults of Wardha 
by ATP-III criteria [38]. 
In a study involving 150 rural women in a primary health centre of 
Tamil Nadu the prevalence of metabolic syndrome was found to be 
36% based on the modified NCEP ATP III criteria [39]. 
Studies involving a larger population will help us to understand the 
impact of impaired fasting glycemia in the pathogenesis of metabolic 
syndrome and its complications. 
CONCLUSION 
The result of this study involving patients with impaired fasting 
glycemia shows an increased prevalence of metabolic syndrome. 
Identification of individuals with impaired fasting glycemia and 
screening for the presence of metabolic syndrome will help to 
decrease the morbidity associated with this condition. This study 
highlights the importance of impaired fasting glycemia in the 
pathogenesis of metabolic syndrome. 
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